Quantcast

Latest Abacavir Stories

2014-05-21 12:16:10

IQWiG Added benefit based on fewer side effects / no data for adolescents and pretreated adults who do not require integrase inhibitors Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality...

2014-04-01 16:25:22

GENEVA, April 1, 2014 /PRNewswire/ -- Access to dolutegravir could improve millions of lives in developing countries The Medicines Patent Pool (MPP) and ViiV Healthcare announced a new collaboration on HIV medicines today, signing two licensing agreements to increase access to dolutegravir (DTG), a promising new antiretroviral, for both adult and paediatric care. The agreements would allow generic...

2014-04-01 16:25:15

- Timely collaborations underscore ViiV Healthcare's commitment to increase access to life-saving HIV medicines for children and adults in the developing world LONDON, April 1, 2014 /PRNewswire/ -- ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir (marketed under the name Tivicay®), just two months after its approval by the European Medicines Agency (EMA) and eight months after approval by the US Food and Drug...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.